The development of a novel PARP inhibitor with potent antitumor activity in various tumor xenograft models

被引：0
|
作者：
Park, Ji-Seon [1 ]
Kim, Jang-Hyun [1 ]
Cheon, Kwang-Woo [1 ]
Cho, Bo-Young [1 ]
Kim, Kang-Jeon [1 ]
Lee, Han-Chang [1 ]
Kim, Young-Cheol [1 ]
Oh, Hyung-Chan [1 ]
Lee, Hyun-Ho [1 ]
Kim, Jeong-Min [1 ]
机构：
[1] JEIL Pharm, Yongin, South Korea
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
825
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Novel PARP inhibitors with potent antitumor activity as single-agent and combination therapies
    Wang, Bing
    Chu, Daniel
    Feng, Ying
    Yu, Xin
    Myers, Peter
    Post, Leonard
    Shen, Yucliao
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [22] Assessment of Antitumor Activity for Tumor Xenograft Studies Using Exponential Growth Models
    Wu, Jianrong
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (03) : 472 - 483
  • [23] Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor
    Lee, Myongjae
    Park, Joon-Tae
    Yang, Ji-hun
    Kim, Dohee
    Je, In-Gyu
    Lee, Yoon Suk
    Jeong, Jinah
    Song, Dong Keun
    Park, Soobong
    Lee, Hong-Sub
    Kim, Yong-Man
    Lee, Shin-Wha
    Kang, Dong Woo
    Lee, Ha-Young
    Kim, Jung Yong
    Lee, Sungsook
    Baek, Nam Seok
    Kang, Jae-Hoon
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [24] Modeling antitumor activity in xenograft tumor treatment
    Liang, H
    BIOMETRICAL JOURNAL, 2005, 47 (03) : 358 - 368
  • [25] ANTITUMOR ACTIVITY OF COMBINED VEGF AND EGFR INHIBITORS IN XENOGRAFT MODELS OF EGFR INHIBITOR RESISTANCE
    Li, Heyan
    Takayama, Koichi
    Shiraishi, Yoshimasa
    Okamoto, Isamu
    Harada, Taishi
    Nakanishi, Yoichi
    RESPIROLOGY, 2013, 18 : 93 - 93
  • [26] AZD7648, a potent and selective inhibitor of DNA-PK, potentiates activity of the PARP inhibitor olaparib resulting in sustained anti-tumour activity in xenograft and PDX models
    Ramos-Montoya, Antonio
    Fok, Jacqueline H.
    James, Neil
    Follia, Valeria
    Vazquez-Chantada, Mercedes
    Wijnhoven, Paul
    O'Connor, Lenka Oplustil
    Karmokar, Ankur
    Staniszewska, Anna
    Dean, Emma
    Hollingsworth, Simon J.
    Davies, Barry
    Cadogan, Elaine B.
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
    Yesim Gökmen-Polar
    Yi Liu
    Rachel A. Toroni
    Kerry L. Sanders
    Rutika Mehta
    Sunil Badve
    Christian Rommel
    George W. Sledge
    Breast Cancer Research and Treatment, 2012, 136 : 673 - 682
  • [28] Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
    Goekmen-Polar, Yesim
    Liu, Yi
    Toroni, Rachel A.
    Sanders, Kerry L.
    Mehta, Rutika
    Badve, Sunil
    Rommel, Christian
    Sledge, George W., Jr.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 673 - 682
  • [29] Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
    Kodama, Tatsushi
    Tsukaguchi, Toshiyuki
    Yoshida, Miyuki
    Kondoh, Osamu
    Sakamoto, Hiroshi
    CANCER LETTERS, 2014, 351 (02) : 215 - 221
  • [30] SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models
    Chen, Xin
    Ji, Pan
    Yang, Hui-Wen
    Yang, Ling-Ling
    Zhou, Shu
    Zhong, Lei
    Ma, Shuang
    Fu, Xiao-Yu
    Zhou, Chan
    Li, Guo-Bo
    Zheng, Ming-Wu
    Wei, Yu-Quan
    Yang, Sheng-Yong
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (01) : 138 - 153
12345